IL10 and neoplasm: The all gathered data indicate that DCs with decreased sensitivity to the negative impact of TME-derived IL-10 are able to elicit the effective immune response, which led to the inhibition of tumor growth, but only when their administration is preceded by the use of chemotherapeutic with immunomodulatory properties.